Try our mobile app

Published: 2022-01-31 09:52:51 ET
<<<  go to RDY company page
EX-99.1 2 drr0360_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

Dr. Reddy’s Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills,

Hyderabad - 500 034, Telangana,

India.

CIN : L85195TG1984PLC004507

 

Tel      : +91 40 4900 2900

Fax     : +91 40 4900 2999

Email : mail@drreddys.com

www.drreddys.com

 

January 29, 2022

 

To,

The Secretary

BSE Limited

National Stock Exchange of India Ltd.

New York Stock Exchange Inc.

NSE IFSC Limited

 

Dear Sir/ Madam,

 

Sub: Form 6-K for the quarter ended December 31, 2021, filed with United States Securities and Exchange Commission.

 

This is to inform you that the Company has filed its unaudited condensed consolidated interim financial statements prepared under IFRS in Form 6-K for the quarter ended December 31, 2021, with the United States Securities and Exchange Commission on January 28, 2022. A copy of the Form 6-K is attached. The Form 6-K is also available on the Company’s website, www.drreddys.com.

 

This is for your information.

 

Yours faithfully,

For Dr. Reddy's Laboratories Limited

 

/s/ Vivek Mittal  
Vivek Mittal  
Global General Counsel and Compliance officer  

 

Encl: As above

CC:- New York Stock Exchange Inc.(Stock Code :RDY)

 NSE IFSC Ltd. (Stock Code: DRREDDY)